Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Aventis Pharma Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:19-03-2012
Disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992
Aventis Pharma Ltd has submitted the disclosure under Regulation 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992 to BSE:Fixes Book Closure for Final Dividend & AGM
Aventis Pharma Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from April 12, 2012 to May 03, 2012 (both days inclusive) for the purpose of Payment of Final Dividend & Annual General Meeting (AGM) of the Company to be held on May 03, 2012.Financial Results & Audit Report for Dec 31, 2011
Aventis Pharma Ltd has informed BSE about the Financial Results & a copy of the Audit Report for the period ended December 31, 2011.Board recommends Final Dividend
Aventis Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 23, 2012, inter alia, has recommended Final Dividend of Rs. 29 per Equity share of Rs. 10 for the year ended December 31, 2011.Board to consider Final Dividend
Aventis Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 23, 2012, for approving the audited Accounts for the year ended December 31, 2011 and also to consider recommendation of final Dividend for the said financial year.Financial Results for Sep 30, 2011
Aventis Pharma Ltd has informed BSE about the Financial Results for the period ended September 30, 2011.Acquisition of Nutraceutical Business of Universal Medicare Private Limited
With reference to the earlier announcement dated August 24, 2011, wherein the Company had stated that the Company had entered into a definitive agreement with Universal Medicare Private Limited to acquire its business of marketing and distribution of branded nutraceutical formulations in India.The transaction was then expected to close in the fourth quarter of 2011, subject to certain conditions precedent....Aventis Pharma Ltd to acquire Universal Medicare's Nutraceutical business in India
Aventis Pharma Ltd has informed BSE regarding a Press Release dated August 24, 2011 titled "Aventis Pharma Ltd to acquire Universal Medicare's Nutraceutical business in India"Press Release:"Aventis Pharma Limited (part of the Sanofi Group) announced August 24th, 2011, that it has entered into a definitive agreement to acquire Universal Medicare Private Limited's business of marketing and distribution of branded nutraceutical formulations...Board declares Interim Dividend
Aventis Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 28, 2011, inter alia, has declared an Interim Dividend of Rs. 4 (Rupees Four only) per Equity Share of Rs. 10 for the financial year ending December 31, 2011.